REGENXBIO Inc. (RGNX) Operating Sales Margin

Graphic logo of regenxbio.com (RGNX)

REGENXBIO Inc. (RGNX) integrates ESG principles and ethics into the development of gene therapies. Operating profitability demonstrates the company's dependence on grants and drug trial results. The absence of a stable cash flow leaves the business vulnerable, as development relies on external capital. The value of -120.40 shapes the current metric, determining the resilience of operating profit to market shocks.

regenxbio.com (RGNX): Operating Profit Rate from 07/04/2022 to 11/20/2026

Analytical breakdowns for REGENXBIO (RGNX)

- share price and consensus valuation forecast:
General company analysis:REGENXBIO Inc., RGNX
Core merchandise of regenxbio.com

Licensing the NAV Technology platform creates a foundation for scalability for REGENXBIO Inc. (RGNX) within the gene therapy sector. Operating margin measures the share of profit from core business operations before taxes and interest, reflecting real-world cost management efficiency. This indicator allows analysts to filter out financial noise and assess the internal viability of the model. Analyzing this metric protects investors from capital losses. The dynamics of these processes are reflected in this operating profitability chart.

Competing companies

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations Stoke Therapeutics|Operating Profitability BioLife Solutions BLFS|Wave Life Sciences (WVE) - Operating Return on Sales|Maze Therapeutics, Inc. - Operating Margin|Profitability of Operations Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operating Profitability|TSHA: Operating Profit Ratio|Operating Profitability uniQure Pharma|MGTX - Operating Profitability Margin|Operating Profitability Solid Biosciences (SLDB)|Ocugen Corp - Return on Sales by Operating Profit|Operating Profitability Pacific Biosciences PACB|Operating Profit Ratio BNTC (Benitec)|Design Corp - Operating Margin|Rocket Pharmaceuticals - Operating Profit Ratio|Return on Sales by Operating Profit 4D Molecular Therapeutics, Inc.|Operating Return on Sales Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operating Margin|Operating Return on Sales Editas EDIT|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability